Provider Summary
Primary Uses
Moderate-to-severe systemic lupus erythematosus in adults on standard therapy (excludes severe active CNS lupus per label considerations).
Mechanism of Action
Type I interferon receptor blocker reduces interferon-mediated inflammation.
Pre-treatment / Baseline Requirement
Screen for active infection; consider vaccination status (herpes zoster risk); baseline CBC/CMP per clinician.
Common side effects
Upper respiratory infection, bronchitis, infusion reactions, herpes zoster.
Serious adverse effects / key risks
Serious infections; hypersensitivity; zoster reactivation.
Referral requirements
Standard infusion referral form + drug-specific checklist
Patient & Caregiver Education
What it treats
Moderate-to-severe systemic lupus erythematosus in adults on standard therapy (excludes severe active CNS lupus
How it works
Type I interferon receptor blocker reduces interferon-mediated inflammation.
Before treatment
Tell your clinician if you have an active infection/fever, are pregnant/planning pregnancy, or have major heart/nerve problems. Depending on the medication, you may need labs or screening tests (e.g., TB/hepatitis) and a vaccine review.
Common side effects
Upper respiratory infection, bronchitis, infusion reactions, herpes zoster.
Get urgent help for:
Serious infections; hypersensitivity; zoster reactivation.
On treatment Day:
Plan to stay for monitoring. If you feel dizzy, drowsy, or unwell afterward, do not drive and follow your clinician’s instructions.